MindMaze AGM: New Board Members Signal Growth Amid Shareholder Veto

GENEVA, SWITZERLAND – June 25, 2026 – MindMaze Therapeutics Holding SA (SIX: MMTX), a global leader in scalable precision neurotherapeutics, concluded its Annual General Meeting (AGM) today with shareholders endorsing the company's overall direction and leadership. However, in a notable act of scrutiny, they rejected a key proposal from the Board of Directors to increase conditional share capital.

The meeting affirmed the company's strategic course by re-electing Chairman Walid Hanna and board members Olaf Blanke and Martin Reiss. It also fortified its leadership by appointing two new directors: Brad Hollinger, the founder and CEO of U.S. healthcare giant Vibra Healthcare, and Zach Henderson, MindMaze Therapeutics' own Chief Executive Officer. While the rejection of the capital increase introduces questions about future financing strategies, the broad approval of financial reports and board appointments signals a foundation of stability as the company sharpens its focus on the neurology market.

Shareholders Block Capital Increase in Strategic Vote

The most significant outcome of the AGM was the shareholders' decision to block a proposed increase in conditional share capital. The proposal failed to achieve the required qualified majority, a development that suggests a divergence between the board's financing strategy and shareholder sentiment. In Switzerland, such a measure typically requires approval from two-thirds of votes cast and an absolute majority of the shares' nominal value represented, indicating a substantial portion of investors were not aligned with the plan.

While the company has not detailed the specific reasons for the dissent, market analysts suggest the rejection could stem from concerns about potential shareholder dilution or questions regarding the company's current valuation. This move could temporarily constrain MindMaze's flexibility in raising capital through equity for future growth initiatives, research and development, or potential acquisitions. The immediate market reaction saw a slight dip in the company's stock price, reflecting investor processing of the news.

This development will likely prompt the company's leadership to explore alternative funding structures to fuel its ambitious expansion plans. The board's next steps in securing capital will be closely watched by investors as MindMaze continues to advance its platform for neurorestorative medicine.

New Board Appointments Fortify Leadership and Strategy

In a move that strongly signals its strategic priorities, MindMaze welcomed two influential leaders to its Board of Directors. The election of Brad Hollinger and Zach Henderson is set to deepen the company's healthcare industry integration and align its governance directly with its operational execution.

Brad Hollinger is the Founder, Chairman, and CEO of Vibra Healthcare, a prominent U.S. operator of critical care and inpatient rehabilitation hospitals. His deep expertise in scaling healthcare services across multi-site systems is particularly relevant. This appointment cements a strategic partnership announced in May 2026 between MindMaze and Vibra Healthcare, which aims to deploy MindMaze's digital neurotherapeutics platform across U.S. health systems. Hollinger's presence on the board provides invaluable insight into the U.S. healthcare landscape, a key market for the company's growth.

Zach Henderson's appointment brings the company's chief executive directly into the boardroom. Henderson, who took the helm as CEO in March 2026, has over 30 years of experience in healthcare technology, with a focus on commercializing solutions for chronic neurological conditions. His mandate is to expand access and scale the adoption of MindMaze's validated platform. His board seat ensures that the company's day-to-day operational strategy is seamlessly integrated with its long-term governance and vision.

A Look at Financials: Investing for Long-Term Neurological Innovation

Despite the veto on new capital, shareholders demonstrated their confidence in the company's financial stewardship by approving the 2025 Annual Report and financial statements. The report, published in April 2026, detailed revenues of CHF 0.6 million against operating expenses of CHF 11.2 million, resulting in a net loss of CHF 9.9 million for the year. According to one analyst, this financial profile is not uncommon for a health technology firm in a critical build-out phase, as it invests heavily in clinical validation, commercial infrastructure, and market access.

These investments are already part of a clear strategic plan. The company's recent focus has been on building its U.S. commercial presence and advancing reimbursement pathways, particularly for its home-based therapy solutions. Underscoring continued investor confidence, MindMaze recently secured CHF 8.0 million in equity financing in May 2026.

Looking ahead, the long-term financial outlook appears promising. Some market analysts forecast that MindMaze will achieve profitability within the next three years, projecting an annual revenue growth rate of nearly 80%. One analyst has even issued a "Strong Buy" rating, suggesting significant upside potential. This optimism is rooted in the company's extensive library of clinical validation and its unique position to address a systemic shortage of specialized neurological clinicians with its scalable, reimbursable solutions.

Sharpening Focus: A Pure-Play Neurology Strategy

The results of the AGM arrive as MindMaze undergoes a significant strategic transformation. The company, formed in late 2025 through a business combination, has been systematically streamlining its operations to become a pure-play leader in neurology. Earlier this month, it announced the divestment of non-neurology legacy operations, a move expected to reduce its cost base by approximately one-third by the third quarter of 2026.

This sharpened focus allows MindMaze to concentrate all its resources on its core mission: redefining the recovery trajectory for patients with stroke, Parkinson's disease, and other neurological disorders. The company's platform, which integrates proprietary sensors, advanced software, and AI-driven analytics, offers a seamless continuum of care from hospital to home.

The strategic partnership with Vibra Healthcare is a cornerstone of this strategy, providing a proven model for scaling its FDA-cleared and CE-marked products in the complex U.S. market. By strengthening its leadership and clarifying its mission, MindMaze is positioning itself to operationalize the future of neurorestorative medicine and deliver value to patients, clinicians, and shareholders alike.